Literature DB >> 24515251

Can the real opportunity cost stand up: displaced services, the straw man outside the room.

Simon Eckermann1, Brita Pekarsky.   

Abstract

In current literature, displaced services have been suggested to provide a basis for determining a threshold value for the effects of a new technology as part of a reimbursement process when budgets are fixed. We critically examine the conditions under which displaced services would represent an economically meaningful threshold value. We first show that if we assume that the least cost-effective services are displaced to finance a new technology, then the incremental cost-effectiveness ratio (ICER) of the displaced services (d) only coincides with that related to the opportunity cost of adopting that new technology, the ICER of the most cost-effective service in expansion (n), under highly restrictive conditions-namely, complete allocative efficiency in existing provision of health care interventions. More generally, reimbursement of new technology with a fixed budget comprises two actions; adoption and financing through displacement and the effect of reimbursement is the net effect of these two actions. In order for the reimbursement process to be a pathway to allocative efficiency within a fixed budget, the net effect of the strategy of reimbursement is compared with the most cost-effective alternative strategy for reimbursement: optimal reallocation, the health gain maximizing expansion of existing services financed by the health loss minimizing contraction. The shadow price of the health effects of a new technology, βc = (1/n + 1/d - 1/m)(-1), accounts for both imperfect displacement (the ICER of the displaced service, d < m, the ICER of the least cost-effective of the existing services in contraction) and the allocative inefficiency (n < m) characteristic of health systems.

Entities:  

Mesh:

Year:  2014        PMID: 24515251     DOI: 10.1007/s40273-014-0140-3

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  22 in total

1.  Economics, public health and health care purchasing: the Tayside experience of programme budgeting and marginal analysis.

Authors:  D A Ruta; C Donaldson; I Gilray
Journal:  J Health Serv Res Policy       Date:  1996-10

2.  Real economics needs to reflect real decisions: a response to Johnson.

Authors:  Mark Sculpher; Karl Claxton
Journal:  Pharmacoeconomics       Date:  2012-02-01       Impact factor: 4.981

Review 3.  Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be?

Authors:  S Birch; A Gafni
Journal:  J Health Econ       Date:  1992-10       Impact factor: 3.883

Review 4.  Programme budgeting and marginal analysis: bridging the divide between doctors and managers.

Authors:  Danny Ruta; Craig Mitton; Angela Bate; Cam Donaldson
Journal:  BMJ       Date:  2005-06-25

Review 5.  How much will Herceptin really cost?

Authors:  Ann Barrett; Tom Roques; Matthew Small; Richard D Smith
Journal:  BMJ       Date:  2006-11-25

6.  The value of implementation and the value of information: combined and uneven development.

Authors:  Elisabeth Fenwick; Karl Claxton; Mark Sculpher
Journal:  Med Decis Making       Date:  2008 Jan-Feb       Impact factor: 2.583

7.  Value of information and pricing new healthcare interventions.

Authors:  Andrew R Willan; Simon Eckermann
Journal:  Pharmacoeconomics       Date:  2012-06-01       Impact factor: 4.981

8.  The option value of delay in health technology assessment.

Authors:  Simon Eckermann; Andrew R Willan
Journal:  Med Decis Making       Date:  2008-05-13       Impact factor: 2.583

9.  Including quality attributes in efficiency measures consistent with net benefit: creating incentives for evidence based medicine in practice.

Authors:  Simon Eckermann; Tim Coelli
Journal:  Soc Sci Med       Date:  2012-11-03       Impact factor: 4.634

10.  Time and expected value of sample information wait for no patient.

Authors:  Simon Eckermann; Andrew R Willan
Journal:  Value Health       Date:  2007-12-17       Impact factor: 5.725

View more
  14 in total

1.  The Irish Cost-Effectiveness Threshold: Does it Support Rational Rationing or Might it Lead to Unintended Harm to Ireland's Health System?

Authors:  James F O'Mahony; Diarmuid Coughlan
Journal:  Pharmacoeconomics       Date:  2016-01       Impact factor: 4.981

2.  What Can We Expect from Value-Based Funding of Medicines? A Retrospective Study.

Authors:  Anthony Harris; Jing Jing Li; Karen Yong
Journal:  Pharmacoeconomics       Date:  2016-04       Impact factor: 4.981

3.  Measuring Public Preferences for Health Outcomes and Expenditures in a Context of Healthcare Resource Re-Allocation.

Authors:  Nicolas Krucien; Nathalie Pelletier-Fleury; Amiram Gafni
Journal:  Pharmacoeconomics       Date:  2019-03       Impact factor: 4.981

4.  NICE's cost-effectiveness range: should it be lowered?

Authors:  J P Raftery
Journal:  Pharmacoeconomics       Date:  2014-07       Impact factor: 4.981

Review 5.  Cost-Effectiveness Thresholds: the Past, the Present and the Future.

Authors:  Praveen Thokala; Jessica Ochalek; Ashley A Leech; Thaison Tong
Journal:  Pharmacoeconomics       Date:  2018-05       Impact factor: 4.981

6.  Behavioral response and cost comparison of manual versus pharmacologic restraint protocols in healthy dogs.

Authors:  Michele Barletta; Marc Raffe
Journal:  Can Vet J       Date:  2016-03       Impact factor: 1.008

7.  Application of the Price-Volume Approach in Cases of Innovative Drugs Where Value-Based Pricing is Inadequate: Description of Real Experiences in Italy.

Authors:  Andrea Messori
Journal:  Clin Drug Investig       Date:  2016-08       Impact factor: 2.859

8.  Achieving allocative efficiency in healthcare: nice in theory, not so NICE in Practice?

Authors:  Mike Paulden; Christopher McCabe; Jonathan Karnon
Journal:  Pharmacoeconomics       Date:  2014-04       Impact factor: 4.981

9.  Better informing decision making with multiple outcomes cost-effectiveness analysis under uncertainty in cost-disutility space.

Authors:  Nikki McCaffrey; Meera Agar; Janeane Harlum; Jonathon Karnon; David Currow; Simon Eckermann
Journal:  PLoS One       Date:  2015-03-09       Impact factor: 3.240

10.  Estimating the opportunity costs of bed-days.

Authors:  Frank G Sandmann; Julie V Robotham; Sarah R Deeny; W John Edmunds; Mark Jit
Journal:  Health Econ       Date:  2017-11-06       Impact factor: 3.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.